Tegafur
Teysuno (tegafur) is a small molecule pharmaceutical. Tegafur was first approved as Teysuno on 2011-03-14. It has been approved in Europe to treat stomach neoplasms.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 12 | 12 | — | 1 | 23 |
| Colorectal neoplasms | D015179 | 1 | 2 | 7 | — | — | 10 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 4 | 2 | — | — | 6 |
| Head and neck neoplasms | D006258 | — | 2 | 1 | — | — | 3 | ||
| Esophageal neoplasms | D004938 | C15 | — | 2 | 1 | — | — | 3 | |
| Adenocarcinoma | D000230 | — | 1 | 1 | — | — | 2 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | 1 | |
| Adjuvant chemotherapy | D017024 | — | — | 1 | — | — | 1 | ||
| Carcinoma | D002277 | C80.0 | — | — | 1 | — | — | 1 | |
| Urinary bladder neoplasms | D001749 | C67 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 5 | — | — | — | 7 |
| Neoplasms | D009369 | C80 | 4 | 2 | — | — | — | 6 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 4 | — | — | — | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | — | 3 | — | — | — | 3 | ||
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 2 | — | — | — | 2 |
| Biliary tract neoplasms | D001661 | C24.9 | — | 2 | — | — | — | 2 | |
| Immunotherapy | D007167 | — | 2 | — | — | — | 2 | ||
| Gastrointestinal neoplasms | D005770 | C26.9 | — | 1 | — | — | — | 1 | |
| Bile duct neoplasms | D001650 | — | 1 | — | — | — | 1 | ||
| Pancreatic ductal carcinoma | D021441 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TEGAFUR |
| INN | tegafur |
| Description | Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c(=O)n(C2CCCO2)cc1F |
Identifiers
| PDB | — |
| CAS-ID | 17902-23-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL20883 |
| ChEBI ID | 32188 |
| PubChem CID | 288216 |
| DrugBank | — |
| UNII ID | 1548R74NSZ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000088975 | DPYD, 1679T>G, Ile560Ser | drug response | 2021-05-26 | 1A |
| VCV000088974 | DPYD, 2846A>T, Asp949Val | drug response | 2021-05-24 | 1A |
| VCV000000432 | DPYD, 1905+1G>A | drug response | 2021-05-24 | 1A |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,035 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,269 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more